It also found there was no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites and said the benefits of the vaccine in “combating covid-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects.”
It concluded that the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e. low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (CVST).
It wrote: “These are rare cases – around 20 million people in the UK and EEA had received the vaccine as of March 16 and EMA had reviewed only 7 cases of blood clots in multiple blood vessels (disseminated intravascular coagulation, DIC) and 18 cases of CVST. A causal link with the vaccine is not proven, but is possible and deserves further analysis.”
Earlier this week, Luxembourg joined a growing list of countries to halt vaccinations using the AstraZeneca formula altogether, following concerns it could be linked to blood clots.